Hepatic transplantation: postoperative complications
POSlTRANSPLANT Iymphoproliferative disease (PTLD) is a well-recognized complication of immunosuppression. I Previous reports of patients immunosuppressed with cyclosporine (eyA) revealed a 1.7% incidence of PTLD in solid-organ transplant recipients and a strong association with the Epstein-Barr virus «EBV). ~ The use of FK 506 in clinical trials has resulted in improved patient and graft survival. as well as a reduction in the prevalence of infectious complications and as a result infection-related mortality . .I·~ PTLD has also been seen among the complications observed in patients treated with FK 506. having a reported incidence of 0.7% to 1.5%. ~.fI This report descnbes the clinical and pathologic features of PTLD arising In the solid-organ transplant recipients treated primarily with FK 506.